Skip to content
Menu Close Menu
  • Home
  • Our Team
    • Management
    • Board
  • Our Focus
  • Our Pipeline
  • Investors & Media
  • Contact
< Back
Apr 5, 2019 by ReViral Ltd

ReViral to present at Microbiology Society Annual Conference 2019

London, UK, 5th April 2019: ReViral’s Chief Scientific Officer, Stuart Cockerill, will be giving an oral presentation at the Microbiology Society Annual Conference 2019 (8th-11th April) in Belfast. The presentation entitled “Design, identification and clinical progression of RV521, an inhibitor of respiratory syncytial virus fusion” begins at 10:00am on Wednesday 10th April.

Ends

For more information, please contact:

ReViral Ltd

Eddy Littler, CEO
E: elittler@reviral.co.uk
T: +44 (0) 1438 906761

FTI Consulting (PR Advisors to ReViral)

Irma Gomez-Dib (US) +1 212 850 5761
Simon Conway (UK) +44 20 3727 1000
Email: reviral@fticonsulting.com

Notes to Editors

About ReViral

ReViral is a clinical-stage company focused on developing novel, anti-viral compounds that target respiratory syncytial virus (RSV). Founded in 2011, ReViral has an experienced R&D leadership team with a successful track record in antiviral drug discovery and development. The company has developed a novel antiviral programme targeting RSV fusion with highly potent, orally bioavailable inhibitors, strong drug-like characteristics and good pharmacokinetic properties offering versatility in the route of administration. The lead candidate RV521 completed a Phase IIa study in adult volunteers showing high potency and excellent safety. The company also has an RSV replication programme at an earlier stage of development and plans to expand its pipeline. In August 2018, ReViral completed a $55 million Series B funding round from a group of leading venture capital investors jointly led by New Leaf Venture Partners and Novo Ventures, part of Novo Holdings A/S, with additional new investment from Perceptive Advisors. Existing investors Andera Partners, OrbiMed and Brace Pharma Capital also participated in the fundraise.

About RV521

RV521 is an orally available small molecule antiviral fusion inhibitor being evaluated for the treatment of RSV. RV521 blocks RSV replication by inhibiting RSV F-mediated fusion of RSV to the host cell. In 2018, RV521 generated positive results in a Phase IIa RSV challenge study in healthy adult volunteers, producing statistically significant reductions in viral load and clinical symptoms. In Phase I clinical studies RV521 showed excellent exposure with no serious adverse events. Pre-clinical toxicity tests in adult and juvenile species showed RV521 to have an excellent safety profile with an attractive margin over therapeutic doses.

About Respiratory Syncytial Virus (RSV)

RSV is a pathogen that infects the human respiratory tract, potentially leading to bronchiolitis and pneumonia. While most (but not all) otherwise healthy people recover from the virus, there is an increased risk of severe disease and death in premature infants, individuals with certain pulmonary conditions, the elderly and those who are immune suppressed. Globally RSV is responsible for more than 30 million infections every year and as many as 200,000 infant deaths. An estimated 2-3% of all infants under 2 years of age are hospitalised with RSV.

Source: ReViral Ltd.

Archives

Archives

Our Focus: Developing Transformative Antiviral Therapies

Stevenage Bioscience Catalyst
Gunnels Wood Road
Stevenage
Hertfordshire
SG1 2FX, England
info@reviral.co.uk
2530 Meridian Parkway
2nd Floor
Durham
North Carolina
27713, U.S.A.
info@reviral.co.uk
  • Home
  • Our Team
  • Our Focus
  • Our Pipeline
  • Investors & Media
  • Contact
Copyright © 2022 ReViral Ltd. All Rights Reserved.
  • Privacy Policy